Keyphrases
Tissue-engineered Constructs
100%
Heart Failure
100%
Phase I Clinical Trial
100%
Bioengineering
100%
Proposed Design
100%
Xenograft
66%
Chronic Heart Failure
66%
Epicardial
66%
Left Ventricle
66%
Fibroblasts
66%
Left Ventricular Remodeling
66%
Tissue Scaffolds
66%
Immune-competent
66%
Human Induced Pluripotent Stem Cell-derived Cardiomyocytes (hiPSC-CMs)
66%
Clinical Trials
33%
Cell-based
33%
Induced Pluripotent Stem Cells (iPSCs)
33%
Growth Factors
33%
Safety Trial
33%
Efficacy Endpoint
33%
Phase I Trial
33%
Extracellular Matrix
33%
Rat Model
33%
Left Ventricular Dysfunction
33%
Immunocompromised Patients
33%
Coronary Artery
33%
Coronary Artery Bypass Grafting
33%
Adverse Events
33%
Ejection Fraction
33%
Diastolic Function
33%
Myocardial Blood Flow
33%
Left Ventricular Function
33%
Severe Adverse Events
33%
Patient Well-being
33%
Yucatan
33%
Mini-swine
33%
Cell Injection
33%
Federal Drug Administration
33%
Preclinical Animal Models
33%
Medicine and Dentistry
Clinical Trial
100%
Congestive Heart Failure
100%
Induced Pluripotent Stem Cell
100%
Engineered Tissue
66%
Immunity
66%
Xenograft
66%
Adverse Event
66%
Left Ventricle
66%
Heart Ventricle Remodeling
66%
Cardiac Muscle Cell
66%
Fibroblast
66%
Heart Left Ventricle Failure
33%
Implant
33%
Cell Therapy
33%
Extracellular Matrix
33%
Engineered Cell
33%
Phase I Trials
33%
Coronary Artery Bypass Graft
33%
Ejection Fraction
33%
Coronary Artery
33%
Drug Administration
33%
Diastolic Function
33%
Heart Muscle Blood Flow
33%
Growth Factor
33%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Congestive Heart Failure
100%
Heart Ventricle Remodeling
66%
Adverse Event
66%
Implant
33%
Phase I Trials
33%
Rat Model
33%
Drug Administration
33%
Growth Factor
33%
Minipig
33%
Heart Left Ventricle Failure
33%